ZA201104501B - New therapy and medicament using integrin ligands for treating cancer - Google Patents
New therapy and medicament using integrin ligands for treating cancerInfo
- Publication number
- ZA201104501B ZA201104501B ZA2011/04501A ZA201104501A ZA201104501B ZA 201104501 B ZA201104501 B ZA 201104501B ZA 2011/04501 A ZA2011/04501 A ZA 2011/04501A ZA 201104501 A ZA201104501 A ZA 201104501A ZA 201104501 B ZA201104501 B ZA 201104501B
- Authority
- ZA
- South Africa
- Prior art keywords
- medicament
- treating cancer
- new therapy
- integrin ligands
- integrin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11651908P | 2008-11-20 | 2008-11-20 | |
| US15133609P | 2009-02-10 | 2009-02-10 | |
| US25103009P | 2009-10-13 | 2009-10-13 | |
| PCT/EP2009/008100 WO2010057596A2 (en) | 2008-11-20 | 2009-11-13 | New therapy and medicament using integrin ligands for treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201104501B true ZA201104501B (en) | 2012-03-28 |
Family
ID=42198569
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2011/04501A ZA201104501B (en) | 2008-11-20 | 2011-06-17 | New therapy and medicament using integrin ligands for treating cancer |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20110230423A1 (en) |
| EP (1) | EP2346524A2 (en) |
| JP (1) | JP2012509287A (en) |
| KR (1) | KR20110086757A (en) |
| CN (1) | CN102223915A (en) |
| AU (1) | AU2009317549A1 (en) |
| CA (1) | CA2744134A1 (en) |
| MX (1) | MX2011005256A (en) |
| WO (1) | WO2010057596A2 (en) |
| ZA (1) | ZA201104501B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA016817B1 (en) * | 2006-01-18 | 2012-07-30 | Мерк Патент Гмбх | Specific therapy using integrin ligands for treating cancer |
| JP6426001B2 (en) | 2011-11-17 | 2018-11-21 | グリア エスピー ゼット．オー．オー． | Compositions and methods for treating glioma |
| US9861833B1 (en) * | 2017-03-30 | 2018-01-09 | Norman H. Anderson | Methods of treating melanoma |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5595756A (en) * | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| US6372719B1 (en) * | 1998-03-04 | 2002-04-16 | Jay Cunningham | ανβ3 integrin antagonists in combination with chemotherapeutic agents |
| DE19842415A1 (en) * | 1998-09-16 | 2000-03-23 | Merck Patent Gmbh | Pharmaceutical preparation for treating e.g. tumors, thrombosis or inflammation, contains cyclic pentapeptide integrin inhibitor and chemotherapeutic agent and/or angiogenesis inhibitor |
| US6833373B1 (en) * | 1998-12-23 | 2004-12-21 | G.D. Searle & Co. | Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
| WO2000056350A2 (en) * | 1999-03-22 | 2000-09-28 | Regents Of The University Of Minnesota | Methods of use of beta 1-integrin inhibitors |
| JP2004503540A (en) * | 2000-06-15 | 2004-02-05 | ファルマシア・コーポレーション | Dihydrostilbene alkanoic acid derivatives useful as integrin antagonists |
| EP1299101A4 (en) * | 2000-06-28 | 2004-06-16 | Teva Pharma | Carvedilol |
| CN100571772C (en) * | 2000-11-01 | 2009-12-23 | 默克专利有限公司 | The antagonist of integrin receptors alpha v β 3 and/or α v β 5 is used for the treatment of purposes in the medicine of ophthalmic in preparation |
| WO2005117976A2 (en) * | 2004-06-03 | 2005-12-15 | The Regent Of The University Of California | Method of increasing radiation sensitivity by inhibition of beta one integrin |
| WO2006111925A2 (en) * | 2005-04-18 | 2006-10-26 | Sloan-Kettering Institute For Cancer Research | Inhibition of tumorigenesis by inhibition of a6b4 integrin |
| EA016817B1 (en) * | 2006-01-18 | 2012-07-30 | Мерк Патент Гмбх | Specific therapy using integrin ligands for treating cancer |
| PT2101805E (en) * | 2007-01-18 | 2013-01-31 | Merck Patent Gmbh | Integrin ligands for use in treating cancer |
| EA022831B1 (en) * | 2009-05-20 | 2016-03-31 | Мерк Патент Гмбх | Solid materials of {[2s,5r,8s,11s)-5-benzyl-11-(3-guanidino-propyl)-8-isopropyl-7-methyl-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]acetic acid} and methods for obtaining them |
-
2009
- 2009-11-13 US US13/130,398 patent/US20110230423A1/en not_active Abandoned
- 2009-11-13 WO PCT/EP2009/008100 patent/WO2010057596A2/en active Application Filing
- 2009-11-13 AU AU2009317549A patent/AU2009317549A1/en not_active Abandoned
- 2009-11-13 CN CN200980146314XA patent/CN102223915A/en active Pending
- 2009-11-13 JP JP2011536763A patent/JP2012509287A/en active Pending
- 2009-11-13 KR KR1020117014177A patent/KR20110086757A/en not_active Application Discontinuation
- 2009-11-13 CA CA2744134A patent/CA2744134A1/en not_active Abandoned
- 2009-11-13 MX MX2011005256A patent/MX2011005256A/en not_active Application Discontinuation
- 2009-11-13 EP EP09760485A patent/EP2346524A2/en not_active Ceased
-
2011
- 2011-06-17 ZA ZA2011/04501A patent/ZA201104501B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN102223915A (en) | 2011-10-19 |
| WO2010057596A2 (en) | 2010-05-27 |
| KR20110086757A (en) | 2011-07-29 |
| AU2009317549A1 (en) | 2011-07-07 |
| CA2744134A1 (en) | 2010-05-27 |
| JP2012509287A (en) | 2012-04-19 |
| MX2011005256A (en) | 2011-05-31 |
| US20110230423A1 (en) | 2011-09-22 |
| WO2010057596A3 (en) | 2010-09-16 |
| EP2346524A2 (en) | 2011-07-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200905703B (en) | Specific therapy and medicament using integrin ligands for treating cancer | |
| GB201008930D0 (en) | Methods for stratifying and annotating cancer drug treatment options | |
| IL234064B (en) | A therapeutic combination comprising trastuzumab-mcc-dm1 and docetaxel for use in the treatment of a cancer expressing erbb2 | |
| IL219992A0 (en) | Combination therapy for treating cancer and dianostic assays for use therein | |
| IL228597A0 (en) | Isoindoline compounds for use in the treatment of cancer | |
| EP2532680A4 (en) | Medicinal composition for treating and/or preventing cancer | |
| PL2532366T3 (en) | Pharmaceutical composition for treating and/or preventing cancer | |
| EP2532364A4 (en) | Pharmaceutical composition for treating and/or preventing cancer | |
| EP2165715A4 (en) | Therapeutic agent for cancer, and method for treatment of cancer | |
| HK1249017A1 (en) | A pharmaceutical composition for treating cancer comprising trypsinogen and chymotrypsinogen | |
| EP2142125A4 (en) | Methods, devices, and systems for non-invasive delivery of microwave therapy | |
| ZA201004403B (en) | Therapeutic cancer treatments | |
| EP2125002A4 (en) | Treating skin cancer | |
| EP2046973A4 (en) | For the identification, assessment, and treatment of patients with cancer therapy | |
| EP1985302A4 (en) | Medicament for treatment of tumor and the use thereof | |
| PL2101731T3 (en) | Endoxifen for use in the treatment of cancer | |
| EP2340851A4 (en) | Diagnosis method and therapeutic method for cancer | |
| IL216537A0 (en) | Continuous administration of integrin ligands for treating cancer | |
| EP2148675A4 (en) | Anti-cancer medicine both for diagnosing and treating cancer | |
| HK1247207A1 (en) | New compounds for treating cancer and other disease | |
| EP2144887A4 (en) | Dosages and methods for the treatment of cancer | |
| HUE031337T2 (en) | Opioids for use in the treatment of resistant cancer patients | |
| EP2119708A4 (en) | Tetrahydroquinazoline compounds and their use in preparing medicaments for treating and preventing virosis | |
| IL199911A0 (en) | 3-cinnolinecarboxamide derivatives and their use for treating cancer | |
| ZA201104501B (en) | New therapy and medicament using integrin ligands for treating cancer |